Genitourinary Cancers Symposium Annual Meeting Coverage

First-line Pazopanib May Improve Outcomes in Advanced RCC

First-line Pazopanib May Improve Outcomes in Advanced RCC

Treatment-naïve patients with advanced clear-cell renal cell carcinoma had significantly longer progression-free survival when treated with pazopanib instead of temsirolimus.

Upfront Docetaxel May Have Role in Advanced Prostate Cancer

Upfront Docetaxel May Have Role in Advanced Prostate Cancer

Added to hormone therapy, docetaxel offers a cost effective way to prolong hormone-sensitive disease and improve quality of life years, especially among men with non-metastatic disease, study finds.

Non-urothelial Bladder Cancer Type Affects Disease-Specific Survival

Non-urothelial Bladder Cancer Type Affects Disease-Specific Survival

Patients with bladder adenocarcinomas have the best survival, whereas those with small cell carcinomas of the bladder have the worst.

Metastatic RCC Treatment With Nivolumab Confirmed Safe, Efficacious

Metastatic RCC Treatment With Nivolumab Confirmed Safe, Efficacious

The safety and efficacy of nivolumab for treating metastatic renal cell carcinoma is comparable to that found in the CheckMate 025 trial.

Axitinib-Pembrolizumab Combo Promising for Advanced RCC

Axitinib-Pembrolizumab Combo Promising for Advanced RCC

In a phase Ib study, dual therapy with axitinib and pembrolizumab was well tolerated and demonstrated antitumor activity in treatment-naïve patients with advanced renal cell carcinoma.

Cytoreductive Nephrectomy May Up Survival in Papillary mRCC

Cytoreductive Nephrectomy May Up Survival in Papillary mRCC

Study reveals a 38% decreased risk of death in patients with papillary metastatic renal cell carcinoma who undergo cytoreductive nephrectomy vs those who do not.

Metastatic Kidney Cancer Outcomes Improved With Combined Therapy

Metastatic Kidney Cancer Outcomes Improved With Combined Therapy

Immunotherapy with atezolizumab plus targeted therapy with bevacizumab improves progression-free survival better than sunitinib in patients with untreated metastatic renal cell carcinoma.

Low-Carb Diet Tested as Way to Slow Recurrent Prostate Cancer

Low-Carb Diet Tested as Way to Slow Recurrent Prostate Cancer

In a small phase 2 study of overweight men with recurrent prostate cancer, consuming less than 20 grams of carbohydrates a day resulted in profound weight loss.

PSA Trajectory in nmCRPC Predicts Metastasis, Mortality Risk

PSA Trajectory in nmCRPC Predicts Metastasis, Mortality Risk

Metastasis and death are more likely to occur among patients with relatively high PSA levels at diagnosis of nmCRPC and rising PSA levels during follow-up.

Urologic Cancer Surgery Readmission Rate Highest for RC

Urologic Cancer Surgery Readmission Rate Highest for RC

In a study, nearly 20% of radical cystectomy patients were readmitted for complications within 90 days compared with 1.9% and 5.9% for radical prostatectomy and radical nephrectomy, respectively.

Early Prostate Cancer Salvage ADT Therapy Better

Early Prostate Cancer Salvage ADT Therapy Better

Among men who had PSA failure following radiation therapy for localized PCa, those with a long PSA doubling time had an increased risk of PCa mortality if they started androgen-deprivation therapy later.

Prostate Cancer Pathologic Features Worse in Blacks

Prostate Cancer Pathologic Features Worse in Blacks

Black men undergoing radical prostatectomy for prostate cancer are more likely to have indications for adjuvant radiotherapy compared with white men.

Statin Use May Improve Survival in Advanced Prostate Cancer

Statin Use May Improve Survival in Advanced Prostate Cancer

Statin use is associated with greater overall survival among men with metastatic castration-resistant prostate cancer and improved survival among patients with high-risk prostate cancer.

Negative Repeat Biopsy in PCa Active Surveillance a Positive Sign

Negative Repeat Biopsy in PCa Active Surveillance a Positive Sign

In a study, a negative confirmatory prostate biopsy in prostate cancer patients on active surveillance predicts a lower risk of progressing to treatment.

Earlier Prostate Cancer Drug Use in CRPC Cuts Metastasis Risk

Earlier Prostate Cancer Drug Use in CRPC Cuts Metastasis Risk

In separate studies, apalutamide and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.

Sign Up for Free e-newsletters